Wechselwirkungen · Etcamah
Etcamah 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-153218 · Präparat HOS-100955
OATP1B1 sensitive substrates In vitro data show that camizestrant is an inhibitor of OATP1B1. Therefore, camizestrant may increase the exposure levels of medicinal products that are substrates of OATP1B1 including but not limited to glyburide, and lovastatin. No in vivo clinical data is available. Medicinal products which have a narrow therapeutic index and are sensitive substrates of OATP1B1 should be avoided. Those medicinal products which are sensitive substrates of OATP1B1 are permitted but caution should be exercised and patients monitored closely for possible drug interactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) glyburide (HOS-109273) camizestrant (HOS-153187)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:07:16Z · SHA-256 b50ea6ed7223cee8c2b96a46475d89e0843fb8c57083f80f60c2957e00e303a8 · Passage 748758beafda82be7afe6d5c0a1738d5b9eaedc3e10d6a3752f1b63be1399f49 · Zeichen 3956–4546 im Abschnitt